17.06.2024 14:02:15 - dpa-AFX: *J&J :SUBCUTANEOUS AMIVANTAMAB BLA SUBMITTED TO FDA FOR PATIENTS WITH EGFR-MUTATED NON-SMALL CELL LUNG CANCER

Copyright(c) 2024 RTTNews.com. All Rights Reserved

Copyright RTT News/dpa-AFX
Name WKN Börse Kurs Datum/Zeit Diff. Diff. % Geld Brief Erster Schluss
Johnson & Johnson 853260 NYSE 148,480 10.07.24 19:46:07 +1,430 +0,97% 148,470 148,500 147,260 147,050

© 2000-2024 DZ BANK AG. Bitte beachten Sie die Nutzungsbedingungen | Impressum
2024 Infront Financial Technology GmbH